These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 28346240)
1. Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer. Hwang JY; Kim DH; Bae HS; Kim ML; Jung YW; Yun BS; Seong SJ; Shin E; Kim MK Int J Gynecol Cancer; 2017 May; 27(4):738-742. PubMed ID: 28346240 [TBL] [Abstract][Full Text] [Related]
2. Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study. Kim MK; Seong SJ; Kang SB; Bae DS; Kim JW; Nam JH; Lim MC; Lee TS; Kim S; Paek J J Gynecol Oncol; 2019 Mar; 30(2):e47. PubMed ID: 30740964 [TBL] [Abstract][Full Text] [Related]
3. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer. Kim MK; Seong SJ; Kim YS; Song T; Kim ML; Yoon BS; Jun HS; Lee YH Am J Obstet Gynecol; 2013 Oct; 209(4):358.e1-4. PubMed ID: 23791687 [TBL] [Abstract][Full Text] [Related]
4. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer. Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890 [TBL] [Abstract][Full Text] [Related]
5. Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study. Kim MK; Yoon BS; Park H; Seong SJ; Chung HH; Kim JW; Kang SB Int J Gynecol Cancer; 2011 May; 21(4):673-7. PubMed ID: 21546871 [TBL] [Abstract][Full Text] [Related]
6. Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system. Kim DH; Seong SJ; Kim MK; Bae HS; Kim M; Yun BS; Jung YW; Shim JY J Gynecol Oncol; 2017 Jan; 28(1):e1. PubMed ID: 27670255 [TBL] [Abstract][Full Text] [Related]
7. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer. Chae SH; Shim SH; Lee SJ; Lee JY; Kim SN; Kang SB Int J Gynecol Cancer; 2019 Jan; 29(1):77-85. PubMed ID: 30640687 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study. Leone Roberti Maggiore U; Martinelli F; Dondi G; Bogani G; Chiappa V; Evangelista MT; Liberale V; Ditto A; Ferrero S; Raspagliesi F J Gynecol Oncol; 2019 Jul; 30(4):e57. PubMed ID: 31074240 [TBL] [Abstract][Full Text] [Related]
9. Continued medical treatment for persistent early endometrial cancer in young women. Cho A; Lee SW; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT Gynecol Oncol; 2021 Feb; 160(2):413-417. PubMed ID: 33246662 [TBL] [Abstract][Full Text] [Related]
10. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer. Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741 [TBL] [Abstract][Full Text] [Related]
11. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study. Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893 [TBL] [Abstract][Full Text] [Related]
12. Oral and intrauterine progestogens for atypical endometrial hyperplasia. Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671 [TBL] [Abstract][Full Text] [Related]
13. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH Eur J Cancer; 2013 Mar; 49(4):868-74. PubMed ID: 23072814 [TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women. Zhou H; Cao D; Yang J; Shen K; Lang J Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472 [TBL] [Abstract][Full Text] [Related]
15. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature. Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836 [TBL] [Abstract][Full Text] [Related]
16. Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009). Kim MK; Seong SJ; Lee TS; Kim JW; Nam BH; Hong SR; Suh KS Jpn J Clin Oncol; 2012 Dec; 42(12):1215-8. PubMed ID: 23071290 [TBL] [Abstract][Full Text] [Related]
17. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia. Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315 [TBL] [Abstract][Full Text] [Related]
18. Assessing ovarian stimulation with letrozole and levonorgestrel intrauterine system after combined fertility-sparing approach for atypical endometrial lesions: a retrospective case-control study. Gallo A; Di Spiezio Sardo A; Conforti A; Iorio GG; Zizolfi B; Buonfantino C; De Angelis MC; Strina I; Marrone V; Bifulco G; Alviggi C Reprod Biomed Online; 2024 May; 48(5):103750. PubMed ID: 38430660 [TBL] [Abstract][Full Text] [Related]
19. Long-Term Oncologic and Reproductive Outcomes in Young Women With Early Endometrial Cancer Conservatively Treated: A Prospective Study and Literature Update. Laurelli G; Falcone F; Gallo MS; Scala F; Losito S; Granata V; Cascella M; Greggi S Int J Gynecol Cancer; 2016 Nov; 26(9):1650-1657. PubMed ID: 27654262 [TBL] [Abstract][Full Text] [Related]
20. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]